Skip to main content

Advertisement

Table 1 Patient baseline characteristics

From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Characteristic Safety population (n = 80) Treatment cohort (n = 41)
Age, years   
 Median 59.0 59.0
 Range 35.0–76.0 47.0–74.0
Age distribution, n (%)   
 ≤ 65 years 57 (71.3) 27 (65.9)
 > 65 years 23 (28.8) 14 (34.1)
Sex, n (%)   
 Male 52 (65.0) 25 (61.0)
 Female 28 (35.0) 16 (39.0)
ECOG performance status score, n (%)   
 0 31 (38.8) 19 (46.3)
 1 44 (55.0) 18 (43.9)
 2 5 (6.3) 4 (9.8)
Durie-Salmon stage, n (%)   
 I 6 (7.5) 2 (4.9)
 II 10 (12.5) 7 (17.1)
 III 64 (80.0) 32 (78.0)
Number of prior antimyeloma therapies, n (%)   
 1 9 (11.3) 6 (14.6)
 2 13 (16.3) 10 (24.4)
 3 12 (15.0) 5 (12.2)
 4 12 (15.0) 6 (14.6)
 ≥ 5 34 (42.5) 14 (34.1)
Prior usage of bortezomib and thalidomide, n (%)   
 Used thalidomide previously 59 (73.8) 28 (68.3)
 Used bortezomib previously 57 (71.3) 31 (75.6)
 Used neither thalidomide nor bortezomib 5 (6.3) 1 (2.4)
 Used both thalidomide and bortezomib 41 (51.3) 19 (46.3)
  1. ECOG Eastern Cooperative Oncology Group